Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 19 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research

Catalyst Screening

Enzyme Catalysis

Medicinal Chemistry

Synthetic Chemistry

Analytical Chemistry

Full Time Equivalent(FTE)

Fee For Service(FFS)

Biology Research

Structural Biology

Cell Biology

Enzymology & Molecular Interactions

Antibody Discovery

Translational Medicine

Computational Biology & Molecular Modeling

Early Pharmacokinetics

Radiolabel ADME

02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Consistency Evaluation

Preformulation Study

Formulation Stability Study

GMP-based Clinical Sample Production & Packaging

Pilot-scale Preparation Testing

Laboratory-scale Preparation Testing

Preparation Quality Research

Formulation Technology Research

Analytical Method Development and Quality Control
CMC Filings
03 Preclinical Research
Pharmacology & Pharmacodynamics

Tumor Models

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

Ocular Diseases Models

Cardiovascular Model

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Toxicokinetics

DMPK

In Vitro ADME Assays

In Vivo Pharmacokinetic Assays

Bioanalysis

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

IND Filings
01 One-stop Integrated Services
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Chemical Drug Development
One-stop API Process R&D Department
Medicilon's CDMO Service Platform
Pharmaceutical Research CDMO Service Platform
Translational Medicine Platform
GLP-1 New Drug R&D Service
Botanical Drug Preclinical R&D Technology Platform
Antibody R&D Service
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Safety Assessment Lab of Process Chemistry
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Process Department Solid Form Screening Platform
Green Chemistry Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D
06 Drug Analysis
07 Public Services
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2023-07-27Medicilon Events
The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award
Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award the Medicilon DMPK team the "Best Partner Award" to express their gratitude and recognition.
Learn more
2023-07-27Medicilon Events
Fudan University, School of Management "Science and Technology Entrepreneur Camp" entered Medicilon: "Hardcore Technology" as the background color, Adding "luster" to new drug research and development
On July 14, Professor Xiongwen Lu, Dean of the School of Management of Fudan University, led the professor group of Fudan School of Management and the students of the fifth phase of the Fudan Science and Technology Entrepreneur Camp into the Zhangjiang Park of Shanghai Medicilon Inc. (Medicilon) to conduct a site visit.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CAREERS
Talent Development
Employee Activities
Campus Recruitment
Social Recruitment
Campus Recruitment
Campus Recruitment
Social Recruitment
Social Recruitment
Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon appeared at the 25th SAPA-NE Annual Conference
Dec 28,2022
Medicilon participated in the annual meeting of the American Chinese Biomedical Technology Association on Christmas Eve
The 27th Annual Chinese Biopharmaceutical Association (CBA) Meeting will be held on December 17, 2022, at the Marriott Washingtonian Center in Maryland!
More
Medicilon participated in the annual meeting of the American Chinese Biomedical Technology Association on Christmas Eve
Dec 28,2022
Listed for 3 consecutive years! Medicilon won the "Top 20 Chinese R&D CRO Enterprises in 2022"
Shanghai Medicilon Inc. (Medicilon), as a one-stop pharmaceutical preclinical R&D service platform in China, was once again selected as one of the "Top 20 Chinese R&D CRO Enterprises in 2022" by virtue of its solid R&D strength. This is the 3rd consecutive year that Medicilon has won this honorary title!
More
Listed for 3 consecutive years! Medicilon won the "Top 20 Chinese R&D CRO Enterprises in 2022"
Dec 28,2022
Translational Medicine - Accelerate the R&D process of innovative drugs and precision medicine
The Medicilon translational medicine platform has an experienced professional technical team, starting from the mechanism of action of drug targets and the clinical application of biomarkers, based on the discovery and validation of biomarkers, combining a variety of different technology platforms and state-of-art instruments, and creating multiple bioanalytical methods, to reduce the cost and time of drug R&D, and provide diverse and efficient services for different types of drugs, different kinds of pharmaceutical companies and projects at different R&D stages.
More
Translational Medicine - Accelerate the R&D process of innovative drugs and precision medicine
Dec 22,2022
Medicilon wish you a merry christmas
Christmas is coming up! Wishing you all the Hope, Wonder, and Joy! Have a delicious time!
More
Medicilon wish you a merry christmas
Dec 09,2022
Holiday Promotion: Medicilon Antibody Development Technology Service with Discount Price
Medicilon Antibody Development Technical Service is here to help you develop new drugs with high cost performance, high efficiency and high quality.
More
Holiday Promotion: Medicilon Antibody Development Technology Service with Discount Price
Dec 09,2022
Congratulation to the Expansion of Medicilon Drug Research and Development Laboratory
On December 4th, with the completion of the last concrete pouring, the expansion project of the drug research and development laboratory of Shanghai Medicilon Inc has been completed. This marks the further strengthening of Medicilon's one-stop biopharmacetical preclinical R&D service platform capabilities.
More
Congratulation to the Expansion of Medicilon Drug Research and Development Laboratory
Nov 22,2022
Medicilon and Infinite Intelligence Pharma Reached a Strategic Collaboration
​Recently, Shanghai Medicilon Inc. (Medicilon) signed a strategic collaboration agreement with Infinite Intelligence Pharma (IIP).
More
Medicilon and Infinite Intelligence Pharma Reached a Strategic Collaboration
Nov 22,2022
Medicilon was Elected as the Director Unit of The Listed Companies Association of Shanghai
On November 10, 2022, the Listed Companies Association of Shanghai held the 4th member meeting of the association and the 1st meeting of council of the association through the online platform of East Money information. The meeting was presided over by Yuan Yi, Secretary of the Association, and supervised by the Shanghai Oriental Notary Public Office.
More
Medicilon was Elected as the Director Unit of The Listed Companies Association of Shanghai
Nov 18,2022
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Medicilon offer a full range of chemistry Research services covering all phases of your project requirements, and clients can work with us under either the FFS (project-based payment) or FTE (full-time equivalent service) models.
More
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Nov 08,2022
Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing
On August 29, 2022, Beijing Peptide Biomedical Technology Co., Ltd. (Bejing Peptide) ZT002 injection was approved by the Australian Human Research Ethics Committee for Phase I clinical trials.
More
Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing
Nov 08,2022
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Recently, Shanghai Medicilon Inc. (Medicilon) appointed Dr. Renzong Xie as the Vice President of Toxicology Research Department.
More
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Oct 28,2022
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
On October 19, AnDiCon Bio (AnDiCon) officially launched the phase II/III clinical study of ADC189 tablets, a new class 1 anti-influenza drug. The drug is expected to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China.
More
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
Stock Code
688202

Global

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->